4-Fluoroamphetamine

{{Short description|Psychoactive research chemical}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Use dmy dates|date=October 2020}} {{Drugbox | Verifiedfields = changed | verifiedrevid = 477221808 | image = 4-Fluoroamphetamine.svg | image_class = skin-invert-image | width = 225px | image2 = 4-Fluoroamphetamine molecule ball.png | image_class2 = bg-transparent | alt2 = Ball-and-stick model of the 4-fluoroamphetamine molecule | width2 = 225px

| tradename = | pregnancy_category = N | routes_of_administration = Oral<ref name="Oeri2021">{{cite journal | vauthors = Oeri HE | title = Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy | journal = J Psychopharmacol | volume = 35 | issue = 5 | pages = 512–536 | date = May 2021 | pmid = 32909493 | pmc = 8155739 | doi = 10.1177/0269881120920420 | url = }}</ref> | class =

| legal_BR = F2 | legal_CA = Schedule I | legal_DE = Anlage I | legal_UK = Class A | legal_US = Schedule I | legal_UN = P II | legal_UN_comment = <ref>{{Cite web | title = Substance Details 4-Fluoroamphetamine | url = https://www.unodc.org/LSS/Substance/Details/35999356-e8a6-428b-a537-90e09d258e0c | access-date = 2024-01-22 }}</ref>

| onset = | duration_of_action = 3–7 hours<ref name="Oeri2021" />

| CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 459-02-9 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = S5744XYR1Z | PubChem = 9986 | KEGG = C22767 | ChEMBL = 2009392 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 9592 | synonyms = 4-FA; 4-FMP; ''para''-Fluoroamphetamine; PFA; PAL-303; PAL303; Flux

| IUPAC_name = (''RS'')-1-(4-fluorophenyl)propan-2-amine | C = 9 | H = 12 | F = 1 | N = 1 | SMILES = Fc1ccc(cc1)CC(N)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C9H12FN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = DGXWNDGLEOIEGT-UHFFFAOYSA-N }}

'''4-Fluoroamphetamine''' ('''4-FA'''; '''4-FMP'''; '''PAL-303'''; "'''Flux'''"), also known as '''''para''-fluoroamphetamine''' ('''PFA'''), is a psychoactive research chemical of the phenethylamine and substituted amphetamine chemical classes. It produces stimulant and entactogenic effects. As a recreational drug, 4-FA is sometimes sold along with related compounds such as 2-fluoroamphetamine and 4-fluoromethamphetamine.<ref>{{cite journal | vauthors = Rösner P, Quednow B, Girreser U, Junge T | title = Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) | journal = Forensic Science International | volume = 148 | issue = 2–3 | pages = 143–156 | date = March 2005 | pmid = 15639609 | doi = 10.1016/j.forsciint.2004.05.003 | citeseerx = 10.1.1.670.7372 }}</ref><ref name="Nagai 2007">{{cite journal | vauthors = Nagai F, Nonaka R, Satoh Hisashi Kamimura K | title = The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | journal = European Journal of Pharmacology | volume = 559 | issue = 2–3 | pages = 132–137 | date = March 2007 | pmid = 17223101 | doi = 10.1016/j.ejphar.2006.11.075 }}</ref>

==Usage== thumb|right|4-Fluoroamphetamine

4-FA was popular in the Netherlands where it was predominantly used for its specific effects (77% of users) rather than its legal status (18%).<ref name="Linsen_2015" /> 4-FA has become illegal since May 2017.<ref>{{cite web | title = Het is nu officieel: de partydrug 4-FA is verboden | date = 25 May 2017 | url = https://nos.nl/op3/artikel/2174904-het-is-nu-officieel-de-partydrug-4-fa-is-verboden.html | website = nos.nl | url-status = live | archive-url = https://web.archive.org/web/20170824215837/https://nos.nl/op3/artikel/2174904-het-is-nu-officieel-de-partydrug-4-fa-is-verboden.html | archive-date = 24 August 2017 }}</ref> Since the ban usage has decreased a lot. Accurate statistics of usage are not available until 2020, but submitted samples to get tested were counted. In 2016 1.100 (10%) of samples tested for DIMS were 4-FA samples,<ref name="4-fa factsheet">{{cite web | vauthors = Croes E, de Ruiter N, Wijers L, Niesink R, Brunt T, van Goor M | title = Factsheet 4-FA | location = Netherlands | issue = 3 | date = October 2017 | url = https://www.trimbos.nl/wp-content/uploads/sites/31/2021/09/af1473-factsheet-4-fa.pdf | access-date = 15 December 2025 | publisher = Trimbos-Instituut | language = Dutch }}</ref> in 2024 less than 50 4-FA samples were submitted.<ref name="Hutten_2025">{{cite web | vauthors = Hutten N, Smit Rigter L | title = Jaarbericht 2024 | location = Utrecht, Netherlands | pages = 6 | date = 2025 | url = https://www.trimbos.nl/wp-content/uploads/2025/10/Jaarbericht-DIMS-2024.pdf | access-date = 15 December 2025 | publisher = Trimbos-Instituut | language = Dutch | id = TRI-41-013 }}</ref> In 2020 0,3% of Dutch adults used 4-FA in the previous year, in 2024 this was just 0,1%.<ref name="Monitor_2025">{{cite web | vauthors = Monitor ND | title = NPS 8.2.2 Veranderingen in NPS-gebruik onder volwassenen | location = Utrecht & Den Haag | date = 2025 | url = https://www.nationaledrugmonitor.nl/nps-demografische-kenmerken-algemene-bevolking/#4fa | website = Nationale Drug Monitor | publisher = Trimbos-instituut & WODC | access-date = 15 December 2025 | language = Dutch | trans-title = NPS-usage by adults }}</ref>

===Effects=== The subjective effects of 4-fluoroamphetamine include euphoria which some find similar to the effects of MDMA and amphetamine,<ref name="Linsen_2015">{{cite journal | vauthors = Linsen F, Koning RP, van Laar M, Niesink RJ, Koeter MW, Brunt TM | title = 4-Fluoroamphetamine in the Netherlands: more than a one-night stand | journal = Addiction | volume = 110 | issue = 7 | pages = 1138–1143 | date = July 2015 | pmid = 25808511 | doi = 10.1111/add.12932 }}</ref> increased energy (stimulation), mood elevation, feelings of warmth and empathy, excessive talking, bruxism, and suppressed appetite (anorexic). The general course of effects involves primarily empathogenic effects for the first few hours, which fades out as increased stimulation develops over the next several hours. {{medcn|date=August 2014}}

The dopamine reuptake inhibition produced by 4-FA is stronger than that of either 4-CA or 4-IA.<ref name="MaronaLewicka_1995">{{cite journal | vauthors = Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE | title = Psychostimulant-like effects of p-fluoroamphetamine in the rat | journal = European Journal of Pharmacology | volume = 287 | issue = 2 | pages = 105–113 | date = December 1995 | pmid = 8749023 | doi = 10.1016/0014-2999(95)00478-5 }}</ref> 4-FA also produces less hyperthermia than similar compounds such as PMA, 4-MTA and 4-methylamphetamine.{{medcn|date=August 2014}}

4-FA has been described as producing a very mild "psychedelic" state, intermediate between that of amphetamine and MDMA.<ref name="Kuypers_2019">{{cite journal | vauthors = Kuypers KP, De Sousa Fernandes Perna EB, Theunissen EL, Toennes SW, Mason NL, Hutten NR, Ramaekers JG | title = A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State | journal = J Psychoactive Drugs | volume = 51 | issue = 3 | pages = 225–235 | date = 2019 | pmid = 30676284 | doi = 10.1080/02791072.2019.1569286 | doi-access = free }}</ref> It is unclear whether this is related to induction of monoamine release or serotonin 5-HT2A receptor agonism.<ref name="Kuypers_2019" />

Common acute side effects are nausea, headaches, increased heart rate and insomnia.{{medcn|date=January 2013}}

==Chemistry== 4-FA reacts with reagent testing to give a semi-unique array of colors which can be used to aid its identification.

{| class="wikitable" |+ Final colors produced by reagent tests |- !Reagent !Reaction color |- | Marquis | No reaction<ref name="RTUK 4-FA">{{cite web | title = 4-FA reaction colour results with liebermann and froehde reagent test kits | date = 3 January 2016 | url = https://www.reagent-tests.uk/blog/4-fa-reaction-colour-results-with-liebermann-and-froehde-reagent-test-kits/ | publisher = Reagent Tests UK | access-date = 14 February 2016 | url-status = live | archive-url = https://web.archive.org/web/20160214131923/https://www.reagent-tests.uk/blog/4-fa-reaction-colour-results-with-liebermann-and-froehde-reagent-test-kits/ | archive-date = 14 February 2016 }}</ref> |- | Mandelin | Pale Blue<ref name="RTUK 4-FA"/><ref name="Uchiyama_2008">{{cite journal | vauthors = Uchiyama N, Kawamura M, Kamakura H, Kikura-Hanajiri R, Goda Y | title = [Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part II: Color test and TLC] | journal = Yakugaku Zasshi | volume = 128 | issue = 6 | pages = 981–987 | date = June 2008 | pmid = 18520145 | doi = 10.1248/yakushi.128.981 | url = https://www.jstage.jst.go.jp/article/yakushi/128/6/128_6_981/_pdf | url-status = live | doi-access = free | archive-url = https://web.archive.org/web/20160305020825/https://www.jstage.jst.go.jp/article/yakushi/128/6/128_6_981/_pdf | archive-date = 5 March 2016 }}</ref> |- | Liebermann | Orange<ref name="RTUK 4-FA"/><ref name="Uchiyama_2008" /> |- | Froehde | Faint purple/brown<ref name="RTUK 4-FA"/> or no reaction. |}

==Pharmacology== 4-Fluoroamphetamine is a releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine.<ref>{{cite journal | vauthors = Toennes SW, Schneider D, Pogoda W, Paulke A, Wunder C, Theunissen EL, Kuypers KP, de Sousa Fernandes Perna E, Ramaekers JG | title = Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion | journal = Drug Testing and Analysis | volume = 11 | issue = 7 | pages = 1028–1034 | date = July 2019 | pmid = 30912312 | doi = 10.1002/dta.2595 | s2cid = 85518011 }}</ref> The respective EC50 values are 200 nM, 730 nM, and 37 nM, while the IC50 values are 770 nM, 6800 nM, and 420 nM.<ref name="Nagai 2007" />

The drug shows some affinity for the serotonin 5-HT2A receptor (Ki = 11,300{{nbsp}}nM) and serotonin 5-HT2C receptor (Ki = 7,800{{nbsp}}nM), similar to that of MDMA in the case of the serotonin 5-HT2A receptor (Ki = 5,900{{nbsp}}nM), but far below the affinity of structurally related classical serotonergic psychedelics like 2C-B.<ref name="Kuypers_2019" /><ref name="Rickli_2015">{{cite journal | vauthors = Rickli A, Hoener MC, Liechti ME | title = Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones | journal = Eur Neuropsychopharmacol | volume = 25 | issue = 3 | pages = 365–376 | date = March 2015 | pmid = 25624004 | doi = 10.1016/j.euroneuro.2014.12.012 }}</ref> It has also been shown to act as a very low-potency serotonin 5-HT2B receptor partial agonist ({{Abbrlink|EC50|half-maximal effective concentration}} = 14,400{{nbsp}}nM; {{Abbrlink|Emax|maximal efficacy}} = 58%).<ref name="Rickli_2015" />

4-Fluoroamphetamine has been found to be a weak monoamine oxidase A (MAO-A) inhibitor, with an {{Abbrlink|IC50|half-maximal inhibitory concentration}} of 16,000{{nbsp}}nM.<ref name="ReyesParada_2019">{{cite journal | vauthors = Reyes-Parada M, Iturriaga-Vasquez P, Cassels BK | title = Amphetamine Derivatives as Monoamine Oxidase Inhibitors | journal = Front Pharmacol | volume = 10 | date = 2019 | pmid = 32038257 | pmc = 6989591 | doi = 10.3389/fphar.2019.01590 | article-number = 1590 | doi-access = free }}</ref> For comparison, the {{Abbrlink|IC50|half-maximal inhibitory concentration}} of amphetamine for MAO-A inhibition was 11,000{{nbsp}}nM.<ref name="ReyesParada_2019" />

Regarding the metabolic fate of 4-FA, the C-F bond at the 4-position on the phenyl ring likely resists deactivation in the liver by cytochrome P450 oxidase.<ref>{{cite journal | vauthors = Fisher MB, Henne KR, Boer J | title = The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism | journal = Current Opinion in Drug Discovery & Development | volume = 9 | issue = 1 | pages = 101–109 | date = January 2006 | pmid = 16445122 }}</ref><ref>{{cite journal | vauthors = Toennes SW, Schneider D, Pogoda W, Paulke A, Wunder C, Theunissen EL, Kuypers KP, de Sousa Fernandes Perna E, Ramaekers JG | title = Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion | journal = Drug Testing and Analysis | volume = 11 | issue = 7 | pages = 1028–1034 | date = July 2019 | pmid = 30912312 | doi = 10.1002/dta.2595 | s2cid = 85518011 }}</ref>

===Neurotoxicity=== 4-FA does not cause long-lasting depletion of brain serotonin, unlike its analogs 4-CA and 4-BA.<ref>{{cite journal | vauthors = Harvey JA | title = Neurotoxic action of halogenated amphetamines | journal = Annals of the New York Academy of Sciences | volume = 305 | issue = 1 | pages = 289–304 | date = June 1978 | pmid = 81648 | doi = 10.1111/j.1749-6632.1978.tb31530.x | s2cid = 38386908 | bibcode = 1978NYASA.305..289H }}</ref> This is thought to "reflect the inability of the fluoro-compound to be metabolized in the same way as the other haloamphetamines."<ref name="Fuller_1975">{{cite journal | vauthors = Fuller RW, Baker JC, Perry KW, Molloy BB | title = Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism | journal = Neuropharmacology | volume = 14 | issue = 10 | pages = 739–746 | date = October 1975 | pmid = 1196472 | doi = 10.1016/0028-3908(75)90099-4 | s2cid = 9620299 }}</ref>

Neurotoxicity does not increase down the series of ''para''-halogenated amphetamine derivatives, even though serotonin releasing potency does follow this trend. For example, 4-iodoamphetamine is less toxic than is 4-chloroamphetamine.<ref name="MaronaLewicka_1995" /><ref>{{cite journal | vauthors = Nichols DE, Johnson MP, Oberlender R | title = 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine | journal = Pharmacology, Biochemistry, and Behavior | volume = 38 | issue = 1 | pages = 135–139 | date = January 1991 | pmid = 1826785 | doi = 10.1016/0091-3057(91)90601-W | s2cid = 20485505 | citeseerx = 10.1.1.670.504 }}</ref> Hence, this property is not related to serotonin releasing potency as such, since PAL-287 was reported to be not at all neurotoxic even though it is a powerful 5-HT releasing agent.<ref>{{cite journal | vauthors = Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH | title = Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 313 | issue = 3 | pages = 1361–1369 | date = June 2005 | pmid = 15761112 | doi = 10.1124/jpet.104.082503 | s2cid = 19802702 | author7-link = Bryan Roth }}</ref> It is unclear where 4-methylamphetamine fits in on the neurotoxicity scale. The extensive serotonergic neurotoxicity of 4-chloroamphetamine (and its brominated derivative), and the increased serotonergic toxicity of 4-methylamphetamine<ref>{{cite journal | vauthors = Blanckaert P, van Amsterdam J, Brunt T, van den Berg J, Van Durme F, Maudens K, van Bussel J | title = 4-Methyl-amphetamine: a health threat for recreational amphetamine users | journal = Journal of Psychopharmacology | volume = 27 | issue = 9 | pages = 817–822 | date = September 2013 | pmid = 23784740 | doi = 10.1177/0269881113487950 | s2cid = 35436194 }}</ref> suggest that para-substitution seems to increase overall serotonergic (neuro)toxicity, compared to amphetamine. Exceptions include 4-MTA, a ''para''-substituted, non-neurotoxic amphetamine.<ref name="Huang_1992">{{cite journal | vauthors = Huang X, Marona-Lewicka D, Nichols DE | title = p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent | journal = European Journal of Pharmacology | volume = 229 | issue = 1 | pages = 31–38 | date = December 1992 | pmid = 1473561 | doi = 10.1016/0014-2999(92)90282-9 }}</ref><ref>{{cite journal | vauthors = Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD | title = Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA) | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 279 | issue = 3 | pages = 1261–1267 | date = December 1996 | pmid = 8968349 | doi = 10.1016/S0022-3565(25)21285-X }}</ref><ref>{{cite journal | vauthors = Murphy J, Flynn JJ, Cannon DM, Guiry PJ, McCormack P, Baird AW, McBean GJ, Keenan AK | title = In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine | journal = European Journal of Pharmacology | volume = 444 | issue = 1–2 | pages = 61–67 | date = May 2002 | pmid = 12191583 | doi = 10.1016/S0014-2999(02)01586-8 }}</ref>

===Toxicology=== The LD50 (mouse; i.p.) of 4-FA is 46 mg/kg.<ref>{{cite book | vauthors = Costa E, Garattini S | title = Amphetamines and Related Compounds | location = New York | pages = 28 | date = 1970 | publisher = Raven Press }}</ref>

Fluoroamphetamine (isomer not determined) in a capsule mixed with 25C-NBOMe was associated with three deaths in Melbourne in 2017.<ref>{{Cite web | title = News: March 2017 – Australia: "Ecstasy" capsules containing NPS are related to several deaths and severe intoxications in Melbourne | url = https://www.unodc.org/LSS/announcement/Details/48940b13-df58-4da2-a66b-d54a8f7362f7 | access-date = 2022-02-27 | website = www.unodc.org }}</ref>

==Legal status==

As of October 2015, 4-FA is a controlled substance in China.<ref>{{cite web | title = 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | date = 27 September 2015 | url = http://www.sfda.gov.cn/WS01/CL0056/130753.html | publisher = China Food and Drug Administration | language = zh | access-date = 1 October 2015 | archive-url = https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date = 1 October 2015 | url-status = dead }}</ref> 4-FA is banned in the Czech Republic.<ref>{{cite web | title = Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.) | url = http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | publisher = Ministerstvo zdravotnictví | language = cs | url-status = live | archive-url = https://web.archive.org/web/20160309174659/http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | archive-date = 9 March 2016 }}</ref> As of 25 May 2017 4-FA is a controlled substance in the Netherlands.<ref>{{cite web | vauthors = Van der Velden L | title = Vanaf vandaag is partydrug 4-FA officieel verboden - maar of dat helpt? | date = 25 May 2017 | url = http://www.volkskrant.nl/binnenland/vanaf-vandaag-is-partydrug-4-fa-officieel-verboden-maar-of-dat-helpt~a4496813/ | publisher = de Volkskrant | access-date = 25 May 2017 | language = nl | url-status = live | archive-url = https://web.archive.org/web/20170525093455/http://www.volkskrant.nl/binnenland/vanaf-vandaag-is-partydrug-4-fa-officieel-verboden-maar-of-dat-helpt~a4496813/ | archive-date = 25 May 2017 }}</ref> 4-FA is also controlled in Australia, Belgium, UK, Germany, Israel, Slovakia, Bulgaria, Chile, Brazil, Canada, Croatia, Sweden, New Zealand and France.{{citation needed|date=March 2017}}

4-FA is a controlled substance as of 27 August 2014 in South Korea.<ref>{{Cite web | title = 식약처,'4-플로오로암페타민'등 4개 물질 마약류로 지정 - 보도자료 {{!}} 브리핑룸 {{!}} 대한민국 정책브리핑|url=https://m.korea.kr/briefing/pressReleaseView.do?newsId=155989200#pressRelease|access-date=2025-09-07|website=m.korea.kr}}</ref>

===Finland=== Scheduled in the "government decree on narcotic substances, preparations and plants" and is therefore illegal.<ref>{{cite web | title = FINLEX ® - Ajantasainen lainsäädäntö: Valtioneuvoston asetus huumausaineina… 543/2008 | url = https://finlex.fi/fi/lainsaadanto/2008/543 }}</ref>

===United States=== In the United States, on June 3, 2025 the DEA announced by federal register its intent to place 4-Fluoroamphetamine into Schedule I status with public comments closing on July 3, 2025.<ref>{{cite web |date=3 June 2025 |title=Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I |url=https://www.federalregister.gov/documents/2025/06/03/2025-09988/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i}}</ref> On January 15, 2026 the DEA placed 4-FA in Schedule 1 of the Controlled Substances Act effective February 17, 2026.<ref>{{Cite web |date=2026-01-15 |title=Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I |url=https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i |access-date=2026-01-20 |website=Federal Register |language=en}}</ref>

== See also == * 2-Fluoroamphetamine (2-FA) * 3-Fluoroamphetamine (3-FA) * 3,4-Difluoroamphetamine * 4-Fluoromethamphetamine (4-FMA) * 4-Fluoromethcathinone (4-FMC) * 4'-Fluoro-4-methylaminorex * ''para''-Bromoamphetamine (PBA) * ''para''-Bromomethamphetamine (PBMA)

== References == {{reflist}}

== External links == * [https://www.erowid.org/chemicals/4_fluoroamphetamine/ Erowid: 4-Fluoroamphetamine]

Category:4-Fluorophenyl compounds Category:5-HT2B agonists Category:Designer drugs Category:Entactogens Category:Serotonin-norepinephrine-dopamine releasing agents Category:Substituted amphetamines